Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gastrointestinal carcinoid tumor
Results 1-20 of 20 for your search:
Start Over
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: AAA-III-01, NCI-2012-02037, 2011-005049-11, NCT01578239
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 18
Trial IDs: TED12689, NCI-2014-00195, U1111-1128-5704, NCT01751308
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Pazopanib Hydrochloride in Treating Patients with Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021202, NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, NCT01841736
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients with Primary or Metastatic Gastrointestinal or Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 13-C-0193, NCI-2014-02318, 335154, NCT01967537
A Phase 2 Study of Fosbretabulin in Subjects With Gastrointestinal Neuroendocrine Tumors With Elevated Biomarkers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OX4218s, NCI-2014-02047, NCT02132468
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: OX4219s, NCI-2015-00120, NCT02279602
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 14-C-0000, 150040, 339636, P141605, NCT02315625
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Somatostatin-Receptor Positive Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 19 and over
Trial IDs: NET0017, NCI-2014-01016, 26988, NCI-2014-00101, NCT01980732
Sorafenib Tosylate and Capecitabine in Treating Patients With Advanced Breast or Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HIC # 1112009424, NCI-2013-00893, 1112009424, ONC-2010-35, NCT01640665
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNX5422-CLN-009, NCI-2014-02577, NCT02063958
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 141525, 9605, NCT02192541
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC PHIXXXX, NCI-2014-02475, 9824, NCT02319018
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BrUOG 265, NCI-2015-00258, 9882, NCT02381561
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CGI-061, NCI-2013-01950, NCT02092714
Massage Therapy in Reducing Oxaliplatin-Induced Peripheral Neuropathy in Patients with Gastrointestinal Malignancies
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: 2014-0250, NCI-2015-00386, NCT02221700
18F-MFBG PET/CT in Imaging Patients with Neuroendocrine Malignancies
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 5 and over
Trial IDs: 14-138, NCI-2015-00234, NCT02348749
Gallium Ga 68-edotreotide PET/CT in Diagnosing Patients with Neuroendocrine Tumors
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: 14-226, NCI-2015-00286, NCT02358018
Start Over